

Haemodynamic collapse immediately after transcatheter aortic valve implantation due to dynamic intraventricular gradient: a case report and review of the literature

Nana Endo 💿 ¹, Hisao Otsuki 💿 ¹*, Satoru Domoto 💿 ², and Junichi Yamaguchi 💿 ¹

¹Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan; and ²Department of Cardiovascular Surgery, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan

Received 27 May 2020; first decision 28 July 2020; accepted 17 December 2020

Background	Dynamic intraventricular obstruction after transcatheter aortic valve implantation (TAVI) has been previously reported. There is a risk of haemodynamic collapse in the case of left ventricular outflow tract (LVOT) obstruction due to systolic anterior motion (SAM) of the mitral valve.
Case summary	An 83-year-old woman with aortic stenosis (AS) was referred to our hospital for TAVI. Transthoracic echocar- diography revealed a severely calcified aortic valve with a peak velocity of 6.3 m/s across the valve. Acceleration of blood flow (peak velocity 2.6 m/s) at the LVOT due to a septal bulge was also seen. Transfemoral TAVI was performed, and a 29 mm Evolut PRO was implanted under general anaesthesia. After the implantation, a complete atrioventricular block with junctional rhythm developed, and refractory hypoten- sion occurred immediately. Transoesophageal echocardiography revealed LVOT obstruction due to SAM of the mitral valve associated with severe mitral regurgitation (MR), which was not observed preoperatively. Fluid infu- sion and catecholamine administration were not effective. However, after performing temporary pacing from the right ventricular (RV) apex, the LVOT obstruction and severe MR improved. Her haemodynamics stabilized, and we could complete the procedure. A dual-chamber permanent pacemaker with beta-blocker administration as a longer-term treatment further improved the LVOT obstruction. The patient was finally discharged to a re- habilitation hospital.
Discussion	Alertness and recognition of potential LVOT obstruction after TAVI are important. Pacing from the RV apex, as well as dual-chamber pacing, comprise a less invasive and feasible therapeutic option in such cases.
Keywords	Transcatheter aortic valve implantation • Left ventricular outflow tract obstruction • Systolic anterior motion of the mitral valve • Right ventricular pacing • Case report

Handling Editor: Ruben Casado Arroyo

- Compliance Editor: Abdelrahman Ibrahim Abushouk
- Supplementary Material Editor: Elhosseyn Guella

^{*} Corresponding author. Tel: +81-3-3353-8111, Fax: +81-3-3356-0441, Email: h.otsuki0107@gmail.com

Peer-reviewers: Alberto Bouzas-Mosquera; Livia Gheorghe; Richard Ang; Panagiotis Xaplanteris; Alessia Azzano; Hatem Soliman Aboumarie

[©] The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Learning points

- It is important to determine the risk factors, mechanism, and management of dynamic intraventricular obstruction after transcatheter aortic valve implantation (TAVI).
- Pacing from the right ventricular apex might be an effective therapeutic option for acute haemodynamic collapse after TAVI due to left ventricular outflow tract obstruction caused by systolic anterior motion of the mitral valve.
- Dual-chamber pacemaker implantation with beta-blocker administration could further improve haemodynamics and may be an option for longer-term management in such cases.

Introduction

Transcatheter aortic valve implantation (TAVI) has become a promising procedure in high-risk surgical patients with aortic stenosis (AS).¹ Similar to surgical aortic valve replacement (SAVR), dynamic intraventricular obstruction after TAVI has been reported.^{2,3}

Since the haemodynamic profile of such cases is similar to those of patients with hypertrophic cardiomyopathy, alcohol septal ablation (ASA) has been reported as a bail-out therapeutic choice.^{4,5} However, some cases might not be eligible for ASA due to technical issues. We describe the case of a patient who we successfully treated with medication and dual-chamber pacing after recovery from acute haemodynamic collapse by temporary pacing from the right ventricular (RV) apex. We also present a literature review on significant intraventricular obstruction after TAVI.

Continued	
Time	Events
Day 7	Extubation
Day 12	A dual-chamber pacemaker was implanted.
Day 34	The patient was discharged to a rehabilitation hospital due to post-resuscitation encephalopathy.
9 months later	The patient was alive without cardiac symptom al- though she was in the nursing home because of the progression of cognitive decline and frailty.

Timeline

Time	Events
1 month earlier	The patient was admitted to another hospital due to acute heart failure secondary to severe aortic stenosis. Her symptom was improved by oxygen and diu-
2 weeks earlier	retics, then discharged. She was referred to our hospital in consideration of transcatheter aortic valve implantation (TAVI).
4 days earlier	Admission to our hospital.
Day 0	 TAVI was performed. Haemodynamics collapsed after implantation of Evolut PRO. Severe left ventricular outflow tract obstruction at- tributable to systolic anterior motion of the mi- tral valve was observed. Temporary pacing from the right ventricle apex
Day 1	was effective. The patient experienced cardiopulmonary arrest due to self-removal of the temporary pace- maker because of delirium. A temporary pacing lead was inserted again, and re- turn of spontaneous circulation was achieved 40 min from onset.
	Continued

Case presentation

An 83-year-old woman was admitted to another hospital due to acute heart failure secondary to severe AS. Her initial condition was improved by medical treatment, however, dyspnoea on exertion (New York Heart Association functional Class II) was still observed. Therefore, she was referred to our hospital in consideration of intervention to AS. At the time of admission, she was haemodinamically stable. She had a systolic murmur of Levine IV/VI at the second left sternal border, clear lung sounds, and no oedema of the lower extremities. Transthoracic echocardiography (TTE) revealed a peak velocity of 6.3 m/s, a peak pressure gradient of 158.8 mmHg, and a mean gradient of 97.1 mmHg. Blood flow acceleration (peak velocity: 2.6 m/s) at the left ventricular outflow tract (LVOT) due to septal bulge was also seen. However, systolic anterior motion (SAM) of the mitral valve was not observed, and mitral regurgitation (MR) was mild (Supplementary material online, Videos S1 and S2). The left ventricular wall was concentrically hypertrophied with both the septum and posterior wall measured 19 mm. The LV cavity was relatively small, measuring 42 mm at end-diastole, and the ejection fraction was 66%. Electrocardiography showed 58 b.p.m. under normal sinus rhythm (Figure 1A). Computed tomography showed the annular perimeter at 75.3 mm and an annular area at 424 mm². The basal septum was bulged and led to narrowing of the LVOT (Figure 2). Coronary angiography revealed no obstruction. We decided to perform TAVI due to the patient's age and frailty (Society of Thoracic Surgeons score of 4.34%, clinical frailty scale of 6). Owing to severe calcification leading to LVOT, a self-expanding valve was selected. Transcatheter aortic valve implantation was performed using a transfemoral



Figure I Electrocardiographic findings. (A) Baseline (58 b.p.m.). (B) After implantation of the transcatheter heart valve. Complete atrioventricular block with junctional rhythm (65 b.p.m.). (C) After permanent pacemaker placement (60 b.p.m.).

approach under general anaesthesia, and a 29-mm Evolut PRO (Medtronic, Minneapolis, MN, USA) was implanted after balloon dilatation. Immediately after implantation, a complete atrioventricular (AV) block with junctional rhythm (over 60 b.p.m.) developed (Figure 1B). Shortly after, her haemodynamics collapsed and refractory hypotension occurred. Fluid infusion (over 500 ml) and intravenous administration of dopamine (5 µg/kg/min) were not effective. Bolus infusion of norepinephrine and phenylephrine slightly increased the patient's blood pressure only temporarily. Transoesophageal echocardiography demonstrated normal functioning of the implanted valve and revealed LVOT obstruction attributable to SAM of the mitral valve associated with severe MR (Figure 3, Supplementary material online, Videos S3 and S4). However, after performing temporary pacing from the RV apex at 80 b.p.m., which was higher than the junctional rhythm, the LVOT obstruction and MR decreased. Thereafter, the haemodynamics stabilized. The patient was successfully extubated and transferred to the intensive care unit.

There, hypotension was reproducibly induced by interrupting the pacing. Transthoracic echocardiography revealed SAM of the mitral valve under junctional own beat, which was improved by RV pacing (*Figure 4*, Supplementary material online, *Videos S5* and *S6*). When accidental self-removal of the pacing lead due to delirium occurred, the haemodynamics deteriorated, although junctional rhythm was observed and led to cardiopulmonary arrest. A temporal pacing lead was reinserted emergently while performing resuscitation; thereafter, a return of spontaneous circulation was achieved.

Since severe obstruction was still observed (peak velocity 6.8 m/s) under RV pacing, a beta-blocker (bisoprolol) was administered. However, significant acceleration (peak velocity 3.5 m/s) remained, and the complete AV block was persistent. Therefore, a dual-chamber permanent pacemaker was implanted. The permanent RV lead was placed at the apex because it showed better haemodynamic

effects than those of septal pacing (Supplementary material online, S7). After adjustment of AV synchrony and medication (bisoprolol: 5 mg, enalapril: 5 mg, and amlodipine: 2.5 mg), TTE revealed mild MR with no evidence of SAM, and the LVOT obstruction was almost resolved. The patient developed post-resuscitation encephalopathy, therefore she was finally discharged to a rehabilitation hospital 34 days after TAVI. At the 9-month follow-up, she had no cardiac symptoms although she was in the nursing home because of the progression of cognitive decline and frailty.

Discussion

Dynamic intraventricular obstruction has been reported to occur in approximately 15% of patients undergoing SAVR for AS.⁶ Its predictive factors were small LV diameter, asymmetrical hypertrophy, high ejection fraction, and high valve gradients.⁷ In contrast to hypertrophic obstructive cardiomyopathy, wherein obstruction is usually located in the LVOT, systolic obstruction after aortic valve replacement tends to be seen in the mid-ventricle because most cases involve concentric hypertrophy.^{6,7} However, asymmetrical hypertrophy, which is also seen in patients with AS and a septal bulge as in our case, might induce LVOT obstruction after TAVI. Dynamic LVOT obstruction is a complex phenomenon arising from the interplay of subaortic hypertrophy, LV ejection fraction, venturi effects, and anterior positioning of the mitral valve apparatus. It is associated with SAM of the anterior mitral leaflet, which causes significant MR. The treatment strategy usually focuses on maintaining LV filling pressure, slowing the heart rate to increase the diastolic filling time, and decreasing inotropy. Conservative therapies often improve the haemodynamics in patients with mid-ventricular obstruction.^{2,8,9} However, since LVOT obstruction can further deteriorate the haemodynamics, some cases $1)^{3-5,10-13}$ reportedly require bail-out treatment (Table





Concomitant septal myectomy in high-risk patients undergoing SAVR has been recommended.¹⁴ However, surgical resection might not be feasible for patients undergoing TAVI due to patient comorbidities and frailty. Currently, ASA has been reported to be a bail-out therapeutic choice to manage severe intraventricular gradient after TAVI.^{4,5,10–12} Alcohol septal ablation is less invasive than surgical resection. However, up to 20% of patients might not have an appropriate septal artery.¹⁵ Moreover, ASA requires experienced operators and equipment. Dual-chamber pacing is reported as a therapeutic alternative to hypertrophic obstructive cardiomyopathy and is less invasive than myectomy or ASA.¹⁶ A possible mechanism for its therapeutic effect has been suggested that initiation of electrical impulse at the RV apex alters the systolic contraction sequence of the basal septum. Although the pacing is not considered as the primary therapy for obstruction, cohort studies have indicated that pacing

effectively reduces the LVOT gradient and symptoms.^{16,17} In fact, RV apex pacing was essential in managing the acute haemodynamic collapse in our case. In addition, a dual-chamber pacemaker was also effective in reducing the residual LVOT gradient. A previous paper reported that disordered AV synchrony following TAVI caused intraventricular obstruction.⁹ Increasing the LV filling pressure by maintaining AV synchrony is important to reduce the gradient. Thus, dual-chamber pacing might be considered if there is no haemo-dynamic improvement with a single RV pacing.

Based on our literature review, one article has already reported the effectiveness of pacing in LVOT obstruction after TAVI.¹³ However, we concluded that our case was valuable as the first report to clearly demonstrate the crucial difference in outcomes with and without pacing (*Figure 4*, Supplementary material online, *Videos S5* and S6).



Figure 3 Intraoperative transoesophageal echocardiography after transcatheter aortic valve implantation. (A) Left ventricular outflow tract obstruction with systolic anterior motion of the anterior mitral valve leaflet (arrow). (B) Severe mitral regurgitation (arrow) and turbulent flow of the left ventricular outflow tract (arrowhead). The mitral regurgitation jet is blowing towards the posterior side.



Figure 4 Transthoracic echocardiography after transcatheter aortic valve implantation. (*A*, *B*) Under own junctional rhythm. Left ventricular outflow tract obstruction with systolic anterior motion of the mitral valve (arrow). The anterior mitral leaflet is thickened. (*C*) Systolic anterior motion of the anterior mitral leaflet (arrow) and left ventricular outflow tract obstruction are decreased by right ventricular pacing. (*D*) The peak flow velocity and pressure gradient are 6.8 m/s and 185 mmHg, respectively, even under right ventricular pacing.

	Age (years)	Sex	Pre TTE	Implanted valve	Onset	Symptoms	TTE findings	Treatment
Suh et al. ²	82	ш	AVPG(p) 121 mmHg MVO (PG 12 mmHg)	23 mm Sapien (TF)	1 day later	Hypotension	MVO	Fluid Beta-blocker
Takeda et al. ¹³	91	Σ	AVPG(p) 152 mmHg Septal bulge	26 mm Sapien (TA)	Immediately	Not mentioned	LVOTO (PG 50 mmHg) SAM of the mitral valve MR severe	Beta-blocker Cibenzoline Pacemater *
Soraja et al. ⁴	89	Σ	AVPG(m) 65 mmHg	26 mm Sapien (TA)	1 month later	Exertional dyspnoea	LVOTO (PG 55 mmHg) SAM of the mitral valve	Beta-blocker ASA*
Gerckens et al. ¹¹	88	ш	AVPG(p) 115 mmHg	23 mm Sapien (TF)	12 h later	Hemodynamic collapse	MVO (PG 108 mmHg) SAM of the mitral valve	Fluid, Pacemaker Beta-blocker
Krishnaswam- y et al. ¹⁰	6	ш	AVPG(m) 58 mmHg ASH LVOTO (PG 12.5 mmHe)	23 mm Sapien (TF)	Immediately	Hemodynamic collapse	MR moderate LVOTO (PG 120 mmHg) SAM of the mitral valve MR severe	Emergent ASA Emergent ASA*
Alfonso et al. ⁸	79	щ	AVPG(m) 82 mmHg	26 mm CoreValve	Immediately	Asymptomatic	MVO (PG 120 mmHg)	Asymptomatic
Ibrahim et <i>a</i> l. ⁹	81	ц	AVPG(p) 109 mmHg	29 mm CoreValve (DA)	Immediately	Not mentioned	OVM	Induced by sinus arrest →spontaneous
Leya et <i>a</i> l. ³	87	щ	AVPG(m) 45 mmHg Sigmoid septum	26 mm CoreValve (TF)	Immediately after BAV	Hemodynamic collapse	LVOTO+MVO SAM of the mitral valve MR severe	AV pacemaker Beta-blocker Valve in valve (26 mm CoreValve)*
Yanagiuchi et al. ¹²	83	Σ	ASH, SAM of the mitral valve	26 mm Sapien 3 (TF)	Immediately	Hypotension	LVOTO (PG 121 mmHg)	ASA (ad hoc)*
Kitahara et <i>a</i> l. ⁵	86	ш	AVPG(p) 64 mmHg ASH, SAM of the mitral valve →Disappeared after beta- blocker initiation	23 mm Sapien 3 (TF)	15 min later	Hemodynamic collapse	LVOTO PG >50mmHg SAM of the mitral valve MR severe	Fluid Beta-blocker infusion Emergent ASA [*]

Leya *et al.*³ reported a case in which severe LVOT obstruction was successfully managed by implanting a second self-expandable valve ('valve in valve'). Retaining the radial force at the LVOT might be a solution for LVOT obstruction. However, no report has compared balloon-expandable and self-expandable prosthetic valves. In our review, LVOT obstruction developed regardless of valve type (*Table 1*). From another perspective, prophylactic MitraClip (Abbott, Davis, CA, USA) implantation prior to TAVI was reported to be useful in preventing exacerbation of LVOT obstruction due to SAM.¹⁸ Further studies are warranted to clarify the effectiveness of such novel approaches.

Alertness and recognition of possible LVOT obstruction after TAVI are important. Pacing from the RV apex and dual-chamber pacing comprise a less invasive and feasible therapeutic option in such cases.

Lead author biography



Nana Endo, MD, is a senior resident of cardiology in Tokyo Women's Medical University. She graduated from Tokyo Women's Medical University in 2014. She finished junior resident program in 2016. After completing resident program of emergency medicine, she started her career as cardiologist since 2017. Membership: Japanese Circulation Society. Japanese Association of Cardiovascular Intervention and Therapeutics.

Supplementary material

Supplementary material is available at *European Heart Journal - Case* Reports online.

Acknowledgements

We would like to thank Editage (www.editage.jp) for English language editing.

Slide sets: A fully edited slide set detailing these cases and suitable for local presentation is available online as Supplementary data.

Consent: The authors confirm that written consent for submission and publication of this case report including images and associated text has been obtained from the patient in line with COPE guidance.

Conflict of interest: H.O. and J.Y. report that they belong to the division (Clinical Research division for Cardiovascular Catheter

Intervention) financially supported by donations from Abbott, Boston Scientific, Medtronic, and Terumo. Other authors have no conflict of interest.

Funding: None declared.

References

- Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187–2198.
- Suh WM, Witzke CF, Palacios IF. Suicide left ventricle following transcatheter aortic valve implantation. *Cathet Cardiovasc Intervent* 2010;**76**:616–620.
- Leya F, Tuchek JM, Coats W. Abnormal distortion of aortic corevalve bioprosthesis with suicide left ventricle, aortic insufficiency, and severe mitral regurgitation during transcatheter aortic valve replacement. *Cathet Cardiovasc Intervent* 2016;88:1181–1187.
- Sorajja P, Booker JD, Rihal CS. Alcohol septal ablation after transaortic valve implantation: the dynamic nature of left outflow tract obstruction. *Cathet Cardiovasc Intervent* 2013;81:387–391.
- Kitahara H, Mastuura K, Sugiura A, Yoshimura A, Muramatsu T, Tamura Y et al. Recurrence of left ventricular outflow tract obstruction requiring alcohol septal ablation after transcatheter aortic valve implantation. Case Rep Cardiol 2018;2018:1–3.
- López Ayerbe J, Evangelista Masip A, Armada Romero E, Mateos González M, González Alujas MT, García Del Castillo H *et al.* Predictive factors of abnormal dynamic intraventricular gradient after valve replacement in severe aortic stenosis. *Rev Esp Cardiol* 2002;**55**:127–134.
- Tsuruta H, Hayashida K, Yashima F, Yanagisawa R, Tanaka M, Arai T et al. Incidence, predictors, and midterm clinical outcomes of left ventricular obstruction after transcatheter aortic valve implantation. *Catheter Cardiovasc Interv* 2018; 92:E288–E298.
- Alfonso F, Domínguez L, Rivero F, Benedicto A, Trillo R. Severe intraventricular dynamic gradient following transcatheter aortic valve implantation: suicide ventricle? *EuroIntervention* 2015;11:e1.
- Ibrahim H, Barker CM, Reardon MJ, Kleiman NS. Suicide left ventricle due to conduction disturbance following transcatheter aortic valve replacement and reversal with restoration of sinus rhythm: is there life after death? J Invasive Cardiol 2015;27:E107–E109.
- Krishnaswamy A, Tuzcu EM, Svensson LG, Kapadia SR. Combined transcatheter aortic valve replacement and emergent alcohol septal ablation. *Circulation* 2013; 128:e366–e368.
- Gerckens U, Pizzulli L, Raisakis K. Alcohol septal ablation as a bail-out procedure for suicide left ventricle after transcatheter aortic valve implantation. J Invasive Cardiol 2013;25:E114–E117.
- Yanagiuchi T, Tada N, Mizutani Y, Matsumoto T, Sakurai M, Ootomo T. Feasibility assessment of alcohol septal ablation in transcatheter aortic valve replacement using multidetector computed tomography. JACC Cardiovasc Interv 2017;10:e7–e9.
- Takeda Y, Nakatani S, Kuratani T, Mizote I, Sakata Y, Torikai K et al. Systolic anterior motion of the mitral valve and severe mitral regurgitation immediately after transcatheter aortic valve replacement. J Echocardiogr 2012;10:143–145.
- Kayalar N, Schaff HV, Daly RC, Dearani JA, Park SJ. Concomitant septal myectomy at the time of aortic valve replacement for severe aortic stenosis. *Ann Thorac Surg* 2010;89:459–464.
- Singh M, Edwards WD, Holmes DR, Tajik AJ, Nishimura RA. Anatomy of the first septal perforating artery: a study with implications for ablation therapy for hypertrophic cardiomyopathy. *Mayo Clin Proc* 2001;**76**:799–802.
- Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Longterm results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. *Circulation* 1994;90:2731–2742.
- Kappenberger L, Linde C, Daubert C, McKenna W, Meisel E, Sadoul N, the PIC Study Group *et al.* Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. *Eur Heart J* 1997;**18**:1249–1256.
- Bode MF, Ahmed AA, Baron SJ, Labib SB, Gadey G. The use of MitraClip to prevent posttranscatheter aortic valve replacement left ventricular "suicide". *Catheter Cardiovasc Interv* 2020;doi: 10.1002/ccd.29100.